Cargando…
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
BACKGROUND: Interstitial lung disease/pneumonitis (ILD/pneumonitis) has been identified as a drug-related adverse event of special interest of trastuzumab deruxtecan (T-DXd), but there were a few reports of T-DXd-related ILD/pneumonitis in clinical practice. METHODS: Between May 25, 2020 (the launch...
Autores principales: | Baba, Tomohisa, Kusumoto, Masahiko, Kato, Terufumi, Kurihara, Yasuyuki, Sasaki, Shinichi, Oikado, Katsunori, Saito, Yoshinobu, Endo, Masahiro, Fujiwara, Yutaka, Kenmotsu, Hirotsugu, Sata, Masafumi, Takano, Toshimi, Kato, Ken, Hirata, Koji, Katagiri, Tomomi, Saito, Hanako, Kuwano, Kazuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687185/ https://www.ncbi.nlm.nih.gov/pubmed/37787866 http://dx.doi.org/10.1007/s10147-023-02414-x |
Ejemplares similares
-
Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non–small cell lung cancer
por: Saito, Yoshinobu, et al.
Publicado: (2021) -
Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
por: Sata, Masafumi, et al.
Publicado: (2021) -
Trastuzumab deruxtecan for breast cancer
Publicado: (2022) -
Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
por: Ikeda, Satoshi, et al.
Publicado: (2021) -
Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
por: Guo, Zihan, et al.
Publicado: (2022)